Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Imaging, Diagnosis, Prognosis

Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma

Eleftherios P. Diamandis, Lee Goodglick, Chris Planque and Mark D. Thornquist
Eleftherios P. Diamandis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee Goodglick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Planque
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark D. Thornquist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-10-3024 Published April 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Our objective was to validate the performance of three new candidate lung cancer biomarkers, pentraxin-3 (PTX3), human kallikrein 11 (KLK11), and progranulin.

Experimental Design: We analyzed by commercial ELISA, and with a blinded protocol, 422 samples from 203 patients with lung carcinoma, 180 individuals with high risk for lung cancer (heavy smokers), and 43 individuals with cancers other than lung. All samples were obtained from the Early Detection Research Network (Reference set A).

Results: We found that progranulin and KLK11 were not informative lung cancer biomarkers, with areas under the receiver operating characteristic curve (AUC; ROC), close to 0.50. However, PTX3 was an informative lung cancer biomarker, with considerable ability to separate lung cancer patients from high-risk controls. At 90% and 80% specificity, the sensitivities versus the high-risk control group were 37% and 48%, respectively. The discriminatory ability of PTX3 was about the same with all major subtypes and histotypes of lung cancer. The AUC of the ROC curves increased according to the disease stage, from 0.64 (stage I) to 0.72 (stage IV).

Conclusion: PTX3, but not KLK11 or progranulin, is a new serum biomarker for lung carcinoma. Its diagnostic sensitivity and specificity is similar to other clinically used lung cancer biomarkers. More studies are needed to establish if PTX3 has clinical utility for lung cancer diagnosis and management. Clin Cancer Res; 17(8); 2395–9. ©2011 AACR.

Translational Relevance

We report for the first time that pentraxin-3, a molecule that is involved with innate immunity and inflammation, is a new biomarker for lung carcinoma. In a blinded validation study, with serum samples obtained from the Early Detection Research Network (Reference set A), serum elevations of this marker were found to occur in approximately 50% of patients of all histological types and the positivity correlated with disease stage. This biomarker could be used either alone, or in combination with other biomarkers, for diagnosis and prognosis of lung carcinoma.

Introduction

Lung cancer is the leading cause of cancer-related mortality in both men and women (1). Lung cancer survival and therapy mainly depend on the histology and stage of the disease at diagnosis (2). Lung cancers are largely classified into 2 histologically distinct subtypes (according to the World Health Organization), based on the size and appearance of the malignant cells: small cell (SCLC) and non–small cell lung carcinoma (NSCLC). NSCLC is the most common and represents approximately 80% of all lung cancers, which can be further subdivided into adenocarcinomas, squamous cell carcinomas (SCC), and large cell carcinomas (3).

The overall 5-year survival rate of lung cancer is less than 15%. This is mainly because most lung cancer patients are diagnosed at advanced stages. Prognosis is more favorable if the lung cancer is detected early (4), by using either computed tomography and chest X-rays, or diagnostic biomarkers. The most widely-used lung cancer biomarkers to date are carcinoembryonic antigen (CEA), SCC antigen, neuron-specific enolase, tissue polypeptide antigen, CYFRA 21-1 (cytokeratine 19 fragment), and progastrin-releasing peptide (5). Although these markers are elevated in serum of a proportion of patients with lung cancer, they are not sensitive or specific enough, alone or in combination, to reliably diagnose asymptomatic patients with lung cancer. Recently, Molina and colleagues (5) reported optimal combinations of currently available lung cancer biomarkers for differentiating between NSCLC and SCLC.

We have recently undertaken a proteomic approach for identifying novel lung cancer biomarkers (6). Proteomic analysis of condition media of 4 lung carcinoma cell lines identified thousands of proteins. This approach (7, 8) was capable in identifying most of the currently known lung cancer biomarkers (6), thus validating its effectiveness. By using bioinformatics and other selection criteria, we were able to identify 5 novel candidate lung cancer biomarkers, namely ADAM-17, osteoprotegerin, pentraxin-3 (PTX3), follistatin, and tumor necrosis factor receptor superfamily member 1A. Analysis of these biomarkers in small numbers of serum samples indicated that they may have value for discriminating lung cancer patients from healthy controls (6).

The Early Detection Research Network (EDRN; http://edrn.nci.nih.gov) is an organization that promotes discovery and validation of cancer biomarkers. One mandate of EDRN is to blindly validate new candidate biomarkers by using serum samples collected by its investigators from various sites, under controlled conditions. We obtained approval to use serum Reference Set A for lung carcinoma, in order to validate 3 biomarker candidates: PTX3; human kallikrein 11 (KLK11), which was previously shown to have some value for lung cancer diagnosis (9); and progranulin, another candidate biomarker identified recently by our group (8). The limited amount of serum provided (100 μL) did not allow for validating the other 4 aforementioned biomarkers. In this paper, we report that with this blinded validation protocol, PTX3 has been shown to be a promising new biomarker for lung carcinoma.

Materials and Methods

Clinical samples

A total of 426 samples from 203 patients diagnosed with lung carcinoma (please see below), 180 individuals at high risk for lung cancer due to a history of cigarette smoking, and 43 individuals with cancers other than lung (25 breast cancer, 18 colon cancer) were enrolled in this study. The lung cancer cases and high-risk controls were at least 40 years old, and the high-risk controls had a cigarette smoking history of at least 30 pack-years. Cases and high-risk controls were frequency matched for age, cigarette smoking history, and center where the specimens were collected. The specimens tested in this study represented a copy of the lung cancer “Reference Set A” (for more details see: http//:edrn.jpl.nasa.gov/resources/samples-reference-sets/LCBG%20protocol%20July%202009.pdf) created by EDRN. Specimens in this reference set were contributed by 4 institutions (MD Anderson Cancer Center; New York University; University of California, Los Angeles; and Vanderbilt University), from archived samples previously collected and stored at −80°C. One aliquot (100 μL of serum) was shipped to the laboratory of Dr. E.P. Diamandis on dry ice. Samples were labeled with a number and they were blinded to the investigators participating in this study. The code was broken only after ELISA analysis was completed and the data submitted to the statistician (Dr. M.D. Thornquist).

ELISA for pentraxin-3, KLK11, and progranulin

In all serum samples, PTX3, KLK11, and progranulin were quantified by using ELISA methodologies. The ELISA for KLK11 was developed in-house and is described elsewhere (10). The ELISA kit for progranulin was purchased from R&D Systems and was used according to the manufacturer's recommendations. Because KLK11 and progranulin were found in this study to be noninformative biomarkers for lung carcinoma, no further details will be provided on either the analytical methods or the clinical data.

PTX3 ELISA kits were purchased from R&D Systems. The assay is based on 2 antibodies, 1 used for capture (monoclonal mouse antibody) and 1 used for detection (biotinylated goat polyclonal antibody). Standardization was achieved by using recombinant, purified PTX3 provided by the manufacturer. The manufacturer's recommendations and protocol were used and serum samples were diluted 3-fold with a 6% bovine serum albumin solution before analysis. The calibration curve was linear from 200 to 20,000 pg/mL and the precision in this range was <10%. All assays were performed in duplicate.

Statistical methods

To evaluate PTX3 for disease screening and diagnosis, we used receiver operating characteristic (ROC) curves, which is the most commonly used summary of classification accuracy. An ROC curve is a plot of the true positive fraction (sensitivity) versus the false positive fraction (one minus the specificity). ROC curves were constructed for the whole group of patients and controls, as well as for case subgroups stratified by histology type and stage and control subgroups stratified by control type (high-risk versus other cancers). The area under the ROC curve (AUC) and the sensitivity of PTX3 at selected specificity cutpoints were also calculated and confidence intervals for these quantities were calculated by bootstrap. Not all patients had complete clinicopathological information and, as deemed necessary, subgroups were combined to increase the statistical power of the calculations. All analyses were performed using Stata version 11 and the pcvsuite of basic ROC analysis commands created by Dr. M. Pepe (11, 12).

Results

The ROC curves for progranulin and KLK11 for the whole patient group versus all controls, or only the high-risk controls, were not informative (the AUCs were close to 0.50 and were not statistically significant; data not shown). For this reason, further statistical analyses for these 2 biomarkers were not performed.

The ROC curve for PTX3 for all cases (N = 203) versus all controls (N = 223), all cases versus high-risk controls (N = 180) and all cases versus other cancer controls (N = 43) are shown in Figure 1 (A, B, C, respectively). PTX3 has significant discriminatory value, especially when comparing all cases versus high-risk controls (B; AUC = 0.69), which is the most relevant group for population screening purposes.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A, ROC curve for pentraxin-3 comparing all cases (N = 203) and all controls (N = 223). AUC = 0.66, 95% CI, 0.61 to 0.71. B, ROC curve for pentraxin-3 comparing all cases (N = 203) and high-risk controls (N = 180). AUC = 0.69, 95% CI, 0.64 to 0.75. C, ROC curve for pentraxin-3 comparing all cases (N = 203) and other cancer controls (N = 43). AUC = 0.54, 95% CI, 0.44 to 0.63.

We further calculated the sensitivity of PTX3 versus high-risk controls and all controls at various specificity cut-offs (Table 1). At 90% and 80% specificity, the sensitivities versus the high-risk controls were 37% and 48%, respectively.

View this table:
  • View inline
  • View popup
Table 1.

Sensitivity and specificity of pentraxin-3 in lung cancer patients

We further performed ROC curve analysis in subgroups of patients, stratified by histology (when available) against the high-risk control group. The ROC curves for these subgroups are shown in Supplementary Figure S1. A summary of the AUCs for each of the subgroups is shown in Table 2. The ROC curves and associated AUCs are generally similar with all subgroups. Thus, we concluded that PTX3 has similar discriminating ability for all of the major subtypes and histotypes of lung cancer.

View this table:
  • View inline
  • View popup
Table 2.

Area under the ROC curve per lung cancer type

There were only 44 patients with known pathological stage: 29 in stage I, 3 in stage II, 8 in stage III, and 4 in stage IV. The small number of patients per stage precludes meaningful analysis but we noticed an increase in AUC (patients versus high-risk controls) from stage I to stage IV, as follows: AUC 0.62 for stage I, 0.64 for stage II, 0.69 for stage III, and 0.72 for stage IV disease (Supplementary Figure S2). For some patients, either the pathological or clinical stage was known. When we analyzed the data according to combined stage (either pathological or clinical stage), we found the following: AUC = 0.61 (stage I; N = 45), AUC = 0.67 (stage II; N = 11), AUC = 0.68 (stage III; N = 16), and AUC = 0.61 (stage IV; N = 10; Supplementary Figure S3).

Discussion

There is currently a plethora of tumor markers for lung cancer. Such markers include CA125, CA19.9, CA15.3, TAG-72.3, CEA, CYFRA21-1, SCC, and NSE (5). None of these markers is suitable for population screening or diagnosis, because of their low sensitivity and specificity, especially in patients with renal failure and liver diseases. Nevertheless, there are significant differences in the performance of these biomarkers in various subtypes of lung carcinoma. For example, CEA, SCC, CA125, CA15.3, and TAG-72.3 are more elevated in NSCLC than in SCLC. In squamous tumors, SCC is more elevated than the other biomarkers, in comparison to adenocarcinomas. On the other hand, NSE is elevated in a much higher proportion of SCLC patients, in comparison to NSCLC patients. Combinations of these biomarkers can aid in the differential diagnosis of NSCLC and SCLC, and some of these biomarkers are also useful for disease monitoring during therapeutic interventions (13). There is still a need for discovering additional lung cancer biomarkers for screening, diagnosis, prognosis, and monitoring response to therapy.

Recently, we and others have used proteomic approaches to identify biomarkers for various cancer types (14–20). In our own proteomic effort, we identified 5 candidate markers that appear to be elevated in serum of lung cancer patients, in comparison to control subjects (6). One of these markers, PTX3, was also identified as a candidate prostate cancer biomarker, by using similar principles (21). In this investigation, we further validated PTX3, along with another 2 candidate biomarkers, KLK11 and progranulin, in a relatively large cohort of patients and controls, obtained from EDRN. The limited serum sample availability precluded us from validating the other 4 candidate lung cancer biomarkers.

Although KLK11 and progranulin were not informative biomarkers in this cohort of lung cancer patients, PTX3 was able to discriminate lung cancer patients from high-risk controls with moderate sensitivity (37% at 90% specificity and 48% at 80% specificity). Such sensitivities and specificities are similar to many other lung cancer biomarkers that are currently used in the clinic (5). It will be interesting, in the future, to investigate if PTX3 can be incorporated into a multiparametric panel with other lung cancer biomarkers. Our data further indicate that PTX3 is equally effective in NSCLC and SCLC, as well as with adenocarcinomas and squamous cell carcinomas. The serum levels of PTX3 appear to correlate positively with tumor stage.

Pentraxins are a superfamily of proteins that are characterized by a structural motif, the pentraxin domain, and are divided into short and long pentraxins. PTX3 is a member of the long pentraxin superfamily and appears to play a role in mediating resistance to fungal pathogens (22). PTX3 is overexpressed in some malignancies, including liposarcomas (23). A role for pentraxin in clearance of apoptotic cells has also been suggested (24). PTX3 expression appears to be regulated by various cytokines, including tumor necrosis factor α (TNFα) and IL1β (25). Under conditions of tissue damage (e.g., myocardial infarction) or infection, PTX3 levels increase more rapidly than C-reactive protein. PTX3 alterations have been seen in sepsis, Aspergillus fumigatus infections, tuberculosis, and dengue.

The elevations of PTX3 in serum of patients with lung cancer are not well understood, but its known overexpression by endothelial cells and macrophages in response to inflammatory signals, as well as its role in clearance of cells undergoing apoptosis (24), suggests that PTX3 may act as a biomarker for lung carcinoma, through its elevation in the inflammatory microenvironment of the tumor and in the clearance of apoptotic cells.

We conclude that PTX3 is a novel biomarker for lung carcinoma, which displays comparable sensitivity and specificity to other currently used lung cancer biomarkers. It appears that the observed serum elevations of PTX3 are associated with inflammation and cancer cell apoptosis around the tumor microenvironment. More studies will be necessary to establish if PTX3 has clinical utility in lung cancer, either alone or as a member of a biomarker panel. In such studies, inclusion of patients with benign lung diseases, in order to further assess the specificity of these biomarkers, would be important. As mentioned earlier, PTX3 may also be elevated in other malignancies such as prostate cancer (21) and liposarcomas (23).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by grants to E.P. Diamandis from Proteomic Methods Inc. and the Natural Sciences and Engineering Research Council of Canada and by the Early Detection Research Network NCI CA86366 (L. Goodglick), Specialized Programs of Research Excellence in Lung Cancer grant P50-CA90388, NCI (L. Goodglick).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

Dr. Eleftherios P. Diamandis is principal investigator of the EDRN. The authors acknowledge provision of serum samples by EDRN and its investigators.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/.

  • Received November 15, 2010.
  • Revision received January 17, 2011.
  • Accepted January 18, 2011.
  • ©2011 American Association for Cancer Research.

References

  1. 1.↵
    1. Jemal A,
    2. Siegel R,
    3. Ward E,
    4. Hao Y,
    5. Xu J,
    6. Thun MJ
    . Cancer Statistics 2009. CA Cancer J Clin 2009;59:225–49.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Schiller JH
    . Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61:3–13.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Brambilla E
    . Classification of broncho-pulmonary cancers (WHO 1999). Rev Mal Respir 2002;19:455–66.
    OpenUrlPubMed
  4. 4.↵
    1. Etzioni R,
    2. Urban N,
    3. Ramsey S,
    4. McIntosh M,
    5. Schwartz S,
    6. Reid B,
    7. et al.
    The case for early detection. Nat Rev Cancer 2003;3:243–52.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Molina R,
    2. Auge JM,
    3. Escudero JM,
    4. Marrades R,
    5. Viñolas N,
    6. Carcereny E,
    7. et al.
    Mucins CA125, CA19.9, CA15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 2008;29:371–80.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Planque C,
    2. Kulasingam V,
    3. Smith CR,
    4. Reckamp K,
    5. Goodglick L,
    6. Diamandis EP
    . Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 2009;8:2746–58.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Kulasingam V,
    2. Diamandis EP
    . Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5:588–99.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Kulasingam V,
    2. Pavlou MP,
    3. Diamandis EP
    . Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010;10:371–8.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Planque C,
    2. Li L,
    3. Zheng Y,
    4. Soosaipillai A,
    5. Reckamp K,
    6. Chia D,
    7. et al.
    A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res 2008;14:1355–62.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Diamandis EP,
    2. Borgono CA,
    3. Scorilas A,
    4. Harbeck N,
    5. Dorn J,
    6. Schmitt M
    . Human kallikrien 11: an indicatior of favorable prognosis in ovarian cancer patients. Clin Biochem 2004;37:823–9.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Pepe MS,
    2. Longton G,
    3. Janes H
    . Estimation and comparison of receiver operating characteristic curves. Stata J 2009;9:1–16.
    OpenUrlPubMed
  12. 12.↵
    1. Janes H,
    2. Longton G,
    3. Pepe MS
    . Accommodating covariates in receiver operating characteristic analysis. Stata J 2009;9:17–39.
    OpenUrlPubMed
  13. 13.↵
    1. Diamandis EP,
    2. Hoffman B,
    3. Sturgeon CM
    . National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers. Clin Chem 2008;54:1935–39.
    OpenUrlFREE Full Text
  14. 14.↵
    1. Kulasingam V,
    2. Diamandis EP
    . Tissue culture-based breast cancer biomarker discovery platform. Int J Cancer 2008;123:2007–12.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Qui J,
    2. Hanash S
    . Autoantibody profiling for cancer detection. Clin Lab Med 2009;29:31–46.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Qiu J,
    2. Choi G,
    3. Li L,
    4. Wang H,
    5. Pitteri SJ,
    6. Pereira-Faca SR,
    7. et al.
    Occurrence of autoantibodies of annexin 1, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060–66.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Shedden K,
    2. Taylor JM,
    3. Enkemann SA,
    4. Tsao MS,
    5. Yeatman TJ,
    6. Gerald WL,
    7. et al.
    Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822–7.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Lehtiö J,
    2. De Petris L
    . Lung cancer proteomics, clinical and technological considerations. J Proteomics 2010;73:1851–63.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Farlow EC,
    2. Patel K,
    3. Basu S,
    4. Lee BS,
    5. Kim AW,
    6. Coon JS,
    7. et al.
    Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010;16:3452–62.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Shah A,
    2. Singh H,
    3. Sachdev V,
    4. Lee J,
    5. Yotsukura S,
    6. Salgia R,
    7. et al.
    Differential serum level of specific haptoglobin isoforms in small cell lung cancer. Curr Proteomics 2010;7:49–65.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Sardana G,
    2. Jung K,
    3. Stepham C,
    4. Diamandis EP
    . Proteomic analysis of conditioned media from PC3, LNCaP and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008;7:3329–38.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Biagi E,
    2. Col M,
    3. Migliavacca M,
    4. Dell'Oro M,
    5. Silvestri D,
    6. Montanelli A,
    7. et al.
    PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immunocompromised pediatric patients. J Pediatr Hematol Oncol 2008;30:881–5.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Willeke F,
    2. Assad A,
    3. Findeisen P,
    4. Schromm E,
    5. Grobholz R,
    6. von Gerstenbergk B,
    7. et al.
    Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer 2005;42:2639–46.
    OpenUrl
  24. 24.↵
    1. Okutani D
    . The role of long pentraxin 3, a new inflammatory mediator in inflammatory responses. Nihon Rinsho Meneki Gakkai Kaishi 2006;29:107–13.
    OpenUrlPubMed
  25. 25.↵
    1. Abderrahim-Ferkoune A,
    2. Bezy O,
    3. Chiellini C,
    4. Maffei M,
    5. Grimaldi P,
    6. Bonino F,
    7. et al.
    Characterization of the long pentraxin PTX3 as a TBFalpha-induced secreted protein of adipose cells. J Lipid Res 2003;44:994–1000.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Clinical Cancer Research: 17 (8)
April 2011
Volume 17, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma
Eleftherios P. Diamandis, Lee Goodglick, Chris Planque and Mark D. Thornquist
Clin Cancer Res April 15 2011 (17) (8) 2395-2399; DOI: 10.1158/1078-0432.CCR-10-3024

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma
Eleftherios P. Diamandis, Lee Goodglick, Chris Planque and Mark D. Thornquist
Clin Cancer Res April 15 2011 (17) (8) 2395-2399; DOI: 10.1158/1078-0432.CCR-10-3024
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • FDOPA PET Survival Predictions for Glioma
  • In vivo Fluorescence Lifetime Imaging for Monitoring the Cancer Treatment
  • Variability in Assessing Response in Metastatic Colorectal Cancer
Show more Imaging, Diagnosis, Prognosis
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement